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C/EBPd is a tumour suppressor transcription factor that induces gene expression involved in suppressing
cell migration. Here we investigate whether C/EBPd-dependent gene expression also affects cell
responses to nanometric topology. We found that ablation of the C/EBPd gene in mouse embryonal
ﬁbroblasts (MEFs) decreased cell size, adhesion and cytoskeleton spreading on 240 nm and 540 nm
nanometric grooves. ChIP-SEQ and cDNA microarray analyses demonstrated that many binding sites for
C/EBPd, and the closely related C/EBPb, exist throughout the mouse genome and control the upregulation
or downregulation of many adjacent genes. We also identiﬁed a group of C/EBPd-dependent, trans-
regulated genes, whose promoters contained no C/EBPd binding sites and yet their activity was regulated
in a C/EBPd-dependent manner. These genes include signalling molecules (e.g. SOCS3), cytoskeletal
components (Tubb2, Krt16 and Krt20) and cytoskeletal regulators (ArhGEF33 and Rnd3) and are possibly
regulated by cis-regulated diffusible mediators, such as IL6. Of particular note, SOCS3 was shown to be
absolutely required for efﬁcient cell spreading and contact guidance on 240 nm and 540 nm nanometric
grooves. C/EBPd is therefore involved in the complex regulation of multiple genes, including cytoskeletal
components and signalling mediators, which inﬂuence the nature of cell interactions with nanometric
topology.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
C/EBP proteins form a highly conserved family of leucine zipper
(bZIP) transcriptional factors that serve as master regulators of
cellular processes such as the cell cycle, differentiation, and
inﬂammatory responses [1]. So far, six C/EBP genes have been iso-
lated (a, b, g, d, ε, and z), although protein numbers may well be
higher due to variation in polypeptide size through alternate
splicing and protein processing [2]. C/EBP isoforms are structurally
similar, displaying a characteristic basic leucine zipper domain at
the C terminus (90% homology between isoforms), which facilitates
dimerization and DNA binding [2]. However, C/EBP isoforms are
functionally and genetically distinct, with their transcriptionaland Systems Biology, College
ity of Glasgow, Room 239,
d Kingdom. Tel.: þ44 (0)141
hen.yarwood@glasgow.ac.uk
-ND license.activation domains less well conserved (<20% sequence identity
between isoforms). This divergence gives rise to the wide range of
cellular responses inwhichC/EBP isoformshavebeen implicated [2].
Attention has recently turned to the functional role of the C/EBPd
isoform, which represents a ubiquitously expressed transcriptional
activator that is robustly induced in a variety of G0 growth arrested
cells [3]. Importantly, “loss of function” alterations in C/EBPd have
been reported in breast cancer [4e6] and acute myeloid leukaemia
(AML) [7] and are generally associated with impaired contact
inhibition, increased genomic instability and increased cell migra-
tion [8]. The use of knockout mice demonstrated that C/EBPd has
a vital role in mammary duct and epithelial cell proliferation [9] as
well as an obligate role in the differentiation of preadipocytes
[10,11]. In addition, recent work suggests that C/EBPd is required
for the maintenance of pluripotency in human limbic stem cells [2].
C/EBPd activity appears to be regulated at a number of levels,
including transcriptional (gene induction by STAT3, Sp1, CREB and
NcoA/SRC-1 [12,13]), post-transcriptional (mRNA stability [14]) and
post-translational (ubiquitinylation [15] and SUMOylation [16])
mechanisms. Certain C/EBP isoforms have also been shown to be
substrates for various protein kinases, including the MAP kinases,
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Fig. 1. Morphology of wild type (WT) and C/EBPd / mouse embryonic ﬁbroblasts (MEFs) cultured on ﬂat or nanogrooved substrates. a) MEF WT and MEF C/EBPd / cells were
cultured on ﬂat or nanogrooved substrates as indicated and stained for actin cytoskeleton (red) and vinculin (green). MEF WT cells had a well developed actin cytoskeleton and
a largely polygonal morphology and became bipolar when cultured on grooves. In contrast C/EBPd / MEFs had a less well developed actin cytoskeleton, were generally smaller
and became very elongated when grown on the grooved substrate. b) MEF WT and MEF C/EBPd / cell area and vinculin intensity were quantiﬁed as described in Materials and
Methods. Results demonstrated that MEF C/EBPd / cells were smaller and had lower levels of vinculin, on both ﬂat and grooved surfaces, than MEF WT cells. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Wiejak et al. / Biomaterials 34 (2013) 1967e1979 1969ERK 1 and 2, and protein kinase C (PKC) [1], and are targets of second
messenger signalling pathways. For example, elevations in the
intracellular levels of cyclic AMP and activation of protein kinase A,
has a direct impact on the induction of the constitutively active C/
EBPd isoform, which, in turn, regulates the acute-phase plasma
protein gene haptoglobin, which is involved in the intestinal
epithelial cell response to inﬂammation [12], whereas cyclic AMP-
activation of exchange protein activated by cyclic AMP 1 (EPAC1),
leads to the C/EBPd-dependent induction of the anti-inﬂammatory
suppressor of cytokine signalling 3 (SOCS3) gene in vascular
endothelial cells [17].
Despite being a transcriptional activator, very few C/EBPd
target genes have been identiﬁed. As a result the mechanisms by
which C/EBPd controls cell adhesion, migration, differentiation
and cell-cycle progression remain poorly understood. Recent
reports have demonstrated that sumoylation of C/EBPd promotes
sequestration to the nuclear periphery, thereby suppressing
expression of C/EBPd-dependent genes associated with cell adhe-
sion, including glycoprotein V, protocadherin 9 and integrin b8
[8,16]. Given this potential link between transcriptional control and
cell adhesion we have used genomic analysis (including gene array
and high resolution DNA sequencing) to investigate the role of C/
EBPd in controlling cell adhesion with biomaterials, comparing
planar and nanometric grooved growth surfaces.
2. Materials and methods
2.1. Materials
Wild type (WT) immortalized mouse embryonic ﬁbroblasts (129SV:C57CI/6,
MEFs) and MEFs containing homozygous deletions of the C/EBPb, or C/EBPd genes
were generous gifts from Prof. Peter Johnson (C/EBPb) and Esta Sterneck (C/EBPd)
from NCI, National Institutes of Health, Frederick, MD. SOCS3 and FAK knockout
MEFs, together with matched WT cells, were gifts from Prof. Margaret Frame,
Edinburgh Cancer Research UK Centre, UK and Dr Timothy Palmer, Institute of
Cardiovascular and Medical Sciences, University of Glasgow, UK, respectively. For-
skolin, and rolipram were purchased from Merck Biosciences (Nottingham, UK).
Anti-SOCS3 and ChIP-grade, anti-C/EBP polyclonal antibodies were from Santa Cruz.
2.2. Generation of grooved and planar growth surfaces
Microstructured quartz substrates were fabricated by acid-cleaning
(7:1H2SO4:H2O2 for 5 min) quartz slides which were then spin-coated with AZ
primer (4000 rpm for 30sec). A layer of Shipley S1818 photoresist (Shipley) was spun
onto to the spin-coated slides and then soft-baked for 30 min in a 90C oven. The
substrates were UV treated on an MA6 mask aligner with exposure energy of ca.
7.1 mJ/cm2 per second in hard contact, through an electron-beam fabricated chrome
mask with 12.5 mmwide lines. The resist was developed (1:1 AZ developer (Micro-
chemicals):water) for 65sec. The substrates were rinsed, dried and then etched in
a trichloromethane environment at a rate of 25 nm/min in a reactive ion etching unit
(RIE80, Plasma Technology) using the polymer pattern as an etch resist to generate
240 or 540 nm deep grooves. The residual resist was removed with acetone and the
slide was blanket etched for a further 1 min to produce a homogenous surface
chemistry. Planar slides were blanket etched to ensure that the chemistry was
comparable with the structured substrates. Quartz substrates were then cleaned in
Caro’s acid solution (2:1 H2SO4:H2O2) for 20 min, rinsed six times with double-
distilled water and air-dried under a Class I or II sterile ﬂow hood. Imprints of the
quartz substrates into polycaprolactone (PCL) were achieved by hot-embossing. The
resulting imprints, 240 nm and 540 nm grooves, were trimmed for use and planar
PCL (Ra of 1.17 nm over 10 mm)was used as a control substrate. The PCL samples were
given a 30 s treatment in oxygen plasma to allow cell attachment (Harrick Plasma,
USA). All PCL substrates were sterilised in ethanol for 30 min, then transferred
through three rinses in sterile 1 PBS and two rinses in complete medium.
2.3. Cell culture and growth of cells on biomaterials
Matched wild type (WT) or homozygous knockout (/) mouse embryonic
ﬁbroblasts (MEFs), for C/EBPb, C/EBPd, SOCS3 or FAK, were maintained in 71% (v/v)
DMEM (Sigma), supplemented with 17.7% (v/v) medium 199, 9% (v/v) FBS, 1% (v/v)
200 mM L-glutamine (Gibco), 0.9% (v/v) 100 mM sodium pyruvate and antibiotics
(6.74 U/ml Penicillin-Streptomycin, 0.2 mg/ml Fungizone) at 37 C in a 5% CO2
environment. Cells were passaged at 70e80% conﬂuence, and the medium was
replaced regularly. Unless otherwise indicated, MEFs were seeded at a density of
1 104 cells/ml on the PCL thumb-embossed substrates with a 24 h culture period.2.4. Immunoﬂuorescence
MEFs were ﬁxed in a 10% (v/v) formaldehyde solution (15min at 37 C), per-
meabilised (5min at 4 C) and blocked in 1% (w/v) BSA/PBS (15min at 37 C). The
samples were then stained at 37oC for 1 h with 1:200 (v/v) anti-vinculin (clone
hVin-1, Sigma) in 1% (w/v) BSA/PBS and 1:500 (v/v) phalloidin-rhodamine (Molec-
ular Probes). In each experiment, two replicas each of planar and nanogroove
topography were stained. Cells were washed 3  5min in 1xPBS containing 0.5% (v/
v) Tween-20, and appropriate biotinylated secondary antibody (Vector Laboratories)
was added at 1:50 in 1% (w/v) BSA/PBS and incubated for a further hour at 37 C.
After washing, 1:50 (v/v) FITC-conjugated streptavidin (Vector Laboratories) was
added to the samples and incubated for 30 min at 4 C followed by washing and
mounting using Vectashield mountant with DAPI nuclear stain (Vector Laborato-
ries). Cell images were captured on a confocal microscope and analysed using Image
J software (NIH). Signiﬁcant changes were determined by one-way ANOVA with
Tukey post-test.
2.5. Microarray analysis
C/EBPbWT, C/EBPb/, C/EBPdWTand C/EBPd / cells were grown on planar
growth surfaces and then incubated in the presence or absence of a combination of
10 mM forskolin plus 10 mM rolipram (F/R) for 5 h at 37 C in 5% (v/v) CO2. Cells were
then washed with 1  1 ml PBS and RNA was isolated using the Qiagen “RNeasy”
Mini Kit according to the manufacturers protocol. RNA samples were additionally
treated with a “DNA-free Kit” (Applied Biosystems) to remove any remaining DNA.
RNA samples were then prepared for Affymetrix whole transcriptome microarray
analysis, using the WT Expression Kit (Ambion) according to the manufacturer’s
instructions. Brieﬂy, reverse transcription was used to prime poly(A) and non-
poly(A), but not ribosomal, mRNA and generate sense strand cDNA for fragmenta-
tion and labelling, using the Affymetrix GeneChip WT Terminal Labelling Kit (PN
900671). Ampliﬁed and biotinylated sense-strand DNA targets were hybridised,
using a Fluidic Station 400,to Affymetrix GeneChip Mouse Gene 2.0 ST Array and
data captured using an Affymetrix GeneChip Scanner 3000 7G. Gene expression
changes were selected where at least one fold change was greater than 2. Grouping
of gene expression data into similarly responsive patterns was done using Treeview
and CLUSTER software [18], freely available from the Eisen lab (http://www.eisenlab.
org/eisen/).
2.6. Chromatin immunoprecipitation and sequencing (ChIP-SEQ) analysis
C/EBPb WT and C/EBPd WT cells were stimulated in the presence or absence of
a combination of 10 mM forskolin plus 10 mM rolipram (F/R) for 5 h at 37 C in 5% (v/
v) CO2. Cells were then ﬁxed and chromatin extracted and sheared using the
enzymatic “CHIP-IT Express Kit” (Active Motif) according to the manufacturer’s
instructions. Sheared chromatin from F/R-treated and non-treated cells was then
immunoprecipitated at 4 C, overnight with 4 mg of either C/EBPb WT or C/EBPd
ChIP-grade antibodies (Santa Cruz). DNA fragments were eluted from immunopre-
cipitated chromatin and used to prepare a ChIP-SEQ DNA library for sequencing
using the “ChIP-SEQ Sample Prep Kit” from Illumina, according to the manufac-
turer’s protocols. Brieﬂy, the ﬁrst step in library preparation was to convert any
overhangs in the ChIP’d DNA into phosphorylated blunt ends. The 30 ends were then
adenylated and adaptors ligated onto the ends of the fragments. The librarywas then
size selected on an agarose gel and eventually enriched by PCR. The enriched library
samples were then loaded onto a ﬂow cell at a concentration of 12pM and cluster
formationwas done on an Illumina Cluster station. Samples were then sequenced on
an Illumina GA IIX giving 76bp reads.
2.7. ChIP-SEQ data analysis
The ChIP DNA was sequenced on an Illumina GA IIx, one lane of the ﬂow
cell per sample. The quality of the reads was assessed using Fastqc (www.
bioinformatics.babraham.ac.uk/projects/fastqc/). The sequence reads were
aligned to the mouse genome (release version mm9) using the bowtie aligner
(version 0.12.7) (bowtie-bio.sourceforge.net/index.shtml) [19], which was set up to
report only uniquely aligning reads. Duplicate reads were removed using Samtools
(version 0.1.18) [20]. The ChIP analysis was performed using the Homer (version
3.9) suite of tools (biowhat.ucsd.edu/homer/ngs/index.html) [21]. The pipeline for
the analysis is shown in Supplementary Fig. 1. Custom scripts were created to
compare the list of known genes closest to ChIP peaks with gene lists generated
from RNA microarray experiments. These corroborated gene lists were visualised
on chromosomes using Circos plots (circos.ca; Supplementary Fig. 2) and Venn
diagram (Fig. 2b).
2.8. Reverse transcription PCR (RT-PCR)
Total RNA isolation was extracted from MEF WT and MEF / cells using an
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. RT-PCR
reactions were carried out using the OneStep RT-PCR Kit from Qiagen. Brieﬂy, 5e
10 ng of RNA per sample was used in 25 ul reaction mixture containing 0.4 mM
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Fig. 2. Results of C/EBPb and C/EBPd ChIP-SEQ and microarray. a) MEF WT cells were incubated in the presence or absence of a combination of the cyclic AMP-elevating agents,
forskolin and rolipram (F/R). Following stimulation cells were ﬁxed, chromatin was isolated and then immunoprecipitated (ChIP’d) with anti-C/EBPb or C/EBPd antibodies, as
described in Materials and methods. ChIP’d DNA samples were then sequenced (ChIP-SEQ) on an Illumina GA IIx DNA sequencer. ChIP analysis of the resulting DNA sequences
was then performed using the Homer (version 3.9) suite of tools (biowhat.ucsd.edu/homer/ngs/index.html). The ﬁgure shows part of the Homer analysis indicating that
aligned sequences from each ChIP experiments contained bone ﬁde C/EBP consensus binding motifs, hence validating the experimental technique. b) MEF WT, MEF C/EBPb / and
MEF C/EBPd / cells were stimulated for 5 h in the presence or absence of F/R. Cells were then harvested, RNA isolated, biotinylated sense-strand DNA synthesised and hybridised
to mouse whole genome GeneChip ST Arrays (Affymatrix). A Venn diagram was then generated to illustrate the degree of overlap between genes identiﬁed by ChIP-SEQ as
containing consensus, F/R-dependent C/EBP-binding sites and F/R-induced changes in MEF gene expression.
J. Wiejak et al. / Biomaterials 34 (2013) 1967e19791970dNTPs and 0.6 mM of each primer. The primer sequences used were mTubb2a
(Fwd 50-TGTGTACTACAATGAAGCTG, Rev 50-GGTACTCCTCTCTGATCTTG), mRnd3
(Fwd 50-ATATGGCCAAGCAGATCGGA, Rev 50-TCACAGTACAGCTCTTCGCT), mKrt16
(Fwd 50-GGAAATGCAGATTGAAAACC; Rev 50-CATACAGTATCTGCCTTTGG), mKrt20
(Fwd 50-ACTACGCACAGATTAAAGAG, Rev 50-TCCAAGTCTGTCTTTTGAAG), mNR4a3
(Fwd 50-ATGAACCCCGACTACACCAA, Rev 50-GTAGAAGGCGGAGACTGCTT), mIRS
(Fwd 50-ACTATATGCCCATGAGCCCC, Rev 50-AGTAAGAGAGGACCGGCTTG), mIL6 (Fwd
50-AAATGATGGATGCTACCAAA, Rev 50-TGACTCCAGCTTATCTGTTA) and mActin (Fwd
50- GGTCATCACTATTGGCAACG, Rev 50-ACGGATGTCAACGTCACACT). Reactions were
carried out in a thermocycler with the following settings; 30 min at 50C (RT-PCR),
15min at 95C (hot-start) and then 30 cycles of 30 s at 94 C, 30 s at 50C followed by
1 min at 72C followed by 10 min at 72C. PCR products were visualised following
ethidium bromide staining on agarose gels.3. Results and discussion
3.1. The role of C/EBPd in controlling cell adhesion and spreading on
nanometric grooves
In order to determine the role of C/EBPd transcription factor in
regulating cell interaction with nanometric topology, embryonal
ﬁbroblasts isolated fromwild type (MEFWT), or transgenic mice in
which both alleles encoding C/EBPd had been deleted (MEF C/EBPd
/), were grown on planar or nanogroove (240 nm or 540 nm
depth, ﬁxed 12.5 mm groove/ridge width (25 mm pitch)) surfaces.
Fig. 3. Gene expression changes from microarray that are also identiﬁed by C/EBPb ChIP-SEQ microarray analysis was carried out on RNA samples isolated from MEF WT, MEF
C/EBPb / and MEF C/EBPd / cells that had been stimulated in the presence or absence (CNTRL) of F/R for 5 h. Gene expression ratios from all cell types were then matched with
genes identiﬁed from ChIP-SEQ as containing C/EBPb binding sites. CLUSTER analysis was then used to generate a dendrogram (on the left) to group together gene changes with
similar expression proﬁles. The enlarged sections on the right represent groups of genes that are either induced (blue) or repressed (yellow) following F/R treatment and display
a dependency for either C/EBPb, C/EBPd or both, as represented by a directional change in gene expression in samples isolated from either MEF C/EBPb / or MEF C/EBPd / cells.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Gene expression changes from microarray that are also identiﬁed by C/EBPd ChIP-SEQ CLUSTER analysis was carried out on gene expression ratio changes that were also
identiﬁed by C/EBPd ChIP-SEQ, as described in the legend to Fig. 3. Enlarged elements of the CLUSTER dendogram on the right represent groups of genes whose responsiveness to
F/R treatment is dependent on the expression of either C/EBPb, C/EBPd, or both.
J. Wiejak et al. / Biomaterials 34 (2013) 1967e19791972
Fig. 5. Gene expression changes from microarray that are also identiﬁed by both C/EBPb and C/EBPd ChIP-SEQ CLUSTER analysis was carried out on microarray gene expression
changes that were also identiﬁed by ChIP-SEQ as genes with consensus binding sites for both C/EBPb and C/EBPd ChIP.
J. Wiejak et al. / Biomaterials 34 (2013) 1967e1979 1973Cells were then ﬁxed and immunostained with anti-actin and anti-
vinculin antibodies (Fig. 1a). From these experiments it was
apparent that MEF WT cells spread normally on planar growth
surfaces, possessing a well developed actin cytoskeleton andadhesion complexes, as indicated by phalloidin and vinculin stain-
ing respectively. In addition, MEF WT cells grown on 240 nm or
540 nm grooves became more elongated and aligned themselves
along the direction of the nanogrooves (Fig. 1a). In contrast, MEF C/
Fig. 6. Gene expression changes from microarray that were not identiﬁed by either C/EBPb or C/EBPd ChIP-SEQ CLUSTER analysis was carried out on microarray gene expression
changes on genes that were not identiﬁed by either C/EBPb or C/EBPd ChIP-SEQ. These gene identities probably represent genes that are either regulated by F/R, independently of
C/EBPb or C/EBPd, or genes that are trans-activated by C/EBPb or C/EBPd.
J. Wiejak et al. / Biomaterials 34 (2013) 1967e19791974
J. Wiejak et al. / Biomaterials 34 (2013) 1967e1979 1975EBPd / cells grown on a ﬂat substrate were more rounded, with
a poorly developed actin cytoskeleton and reduced focal adhesions,
as demonstrated by a reduction in vinculin staining (Fig.1b). MEF C/
EBPd / cells also appeared more stellate with extensive arbor-
isation and, although they underwent contact guidance on nano-
metric grooves, became much more elongated and were much less
spread than MEF WT cells, particularly on 540 nm grooves. These
results demonstrate that the transcription factor C/EBPd plays an
essential role in efﬁcient adhesion and spreading to both planar and
nanometric grooved surfaces. These results are consistent with
a recent report demonstrating that MEF C/EBPd / cells display
increased migration when compared with MEF WT cells in wound
healing assays [22] and suggests that C/EBPd may play a role in
regulating the expression of genes involved in cell adhesion,
movement and spreading.
3.2. Identiﬁcation of C/EBPd consensus binding sites within the
mouse genome
In order to test whether C/EBPd does in fact regulate gene
expression associated with interactions with cell growth surfaces
we carried out genomic analysis to identify the full range of genes
and gene promoters regulated by C/EBPd in MEFs. We stimulated
MEFWTandMEF C/EBPd/ cells for 5 hwith a combination of the
pharmacological agents (F/R), forskolin, which promotes cyclic AMPPrimers
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Fig. 7. RT-PCR analysis demonstrates that C/EBPd is required for the regulation of
genes encoding cytoskeletal components and IL6 MEF WT or MEF / cells were
incubated for 5 h with a combination of forskolin and rolipram (F/R), following which
RNAwas extracted, reverse transcribed and PCR ampliﬁed using the indicated primers.
Results demonstrate that F/R regulates the expression of mRNAs encoding cytoskeletal
components (a) and IL6 (b) in a C/EBPd-dependent manner.synthesis, and rolipram, which inhibits cyclic AMP degradation, to
increase the intracellular levels of C/EBPd protein through the
activation of the C/EBPd gene [17] (Fig. 8). As a comparison, and to
ensure thatwe could identify genes speciﬁcally regulated byC/EBPd,
C/EBPbWTand/ cells were treated in a similar fashion. This was
done becausemany of the cellular actions of C/EBPd are shared by C/
EBPb [17]. Following stimulationMEFWTcells wereﬁxed, lysed and
cellular chromatin isolated, fragmented and immunoprecipitated
(ChIP) with anti-C/EBPd or anti-C/EBPb antibodies. The genomic
DNA associated with ChIP’d samples was then sequenced using
a genome analyser (ChIP-SEQ) to identify the C/EBPd are C/EBPb
binding sites throughout the genome. The sequence reads were
aligned to the mouse genome using the Bowtie aligner (version
0.12.7), whichwas set up to report only uniquely aligning reads, and
duplicate reads were removed using Samtools (version 0.1.18). The
Homer (version 3.9) suite of tools was used to verify that the
majority of reads contained bone ﬁde C/EBP-binding sites (Fig. 2a).
To complement the ChIP-SEQ analysis, mRNAwas also extracted
from F/R-treated MEF C/EBPd WT, MEF C/EBPd /, MEF C/EBPb
WT and MEF C/EBPb / cells. The extracted mRNA was then
converted by reverse transcription to cDNA probes, which were
then hybridised to mouse whole genome microarrays (Affymetrix).
This approach was used so as to determine whether the genes that
contain C/EBP-binding sites, identiﬁed by ChIP-SEQ, are also regu-
lated at the level of transcription in a C/EBP-dependent manner.Antibody
SOCS-3
C/EBPδ
C/EBPδ WT
Tubulin
Forskolin/
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Fig. 8. Deletion of the C/EBPd gene in MEFs blocks the induction of SOCS3 mRNA and
protein MEF WT and MEF C/EBPd / cells were stimulated for 5 h with F/R to elevate
intracellular cyclic AMP levels. This resulted in the induction of C/EBPd and SOCS3
protein in MEF WT, but not MEF C/EBPd /, cells as detected by Western blotting in
the upper panel. Deletion of the C/EBPd gene also blocked the ability of F/R to induce
SOCS3 mRNA expression, as detected by RT-PCR (lower panel).
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Fig. 9. Morphology of Wild Type (WT) and SOCS3 e/e MEFs Cultured on Flat or Nanogrooved Substrates MEF WT and MEF SOCS3 / cells were cultured on ﬂat or nanogrooved
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J. Wiejak et al. / Biomaterials 34 (2013) 1967e19791976Genes identiﬁed as being regulated by F/R, or by deletion of either
C/EBPd or C/EBPb, are listed in Supplementary Data Set 2. Custom
scripts were then created to compare the list of known genes
closest to ChIP peaks with gene lists generated from RNA micro-
array experiments (Supplementary Data Set 1).
These corroborated gene lists were visualised on chromosomes
using Circos plots (circos.ca; Supplementary Fig. 2) and a Venn
diagram (Fig. 2b). From these analyses we identiﬁed over 1100
genes that interact with C/EBPb alone and a similar number thatinteractwith C/EBPd alone (Fig. 2b; Supplementary Data Set 1). Over
650 genes contain binding sites for both C/EBPb and C/EBPd (Fig. 2b;
Supplementary Data Set 1). Generally, C/EBPb and C/EBPd binding
sites were distributed evenly throughout the cellular chromosomes
(Supplementary Fig. 2). Of the approximate 7800 genes identiﬁed
by cDNAmicroarray as being regulated by the F/R treatment regime
(Supplementary Data Set 2), over 500 were identiﬁed as containing
C/EBPb binding sites, over 500 contained C/EBPd binding sites and
over 170 contained binding sites for both C/EBPb and C/EBPd
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J. Wiejak et al. / Biomaterials 34 (2013) 1967e1979 1977(Fig. 2b; Supplementary Data Set 1). These ﬁgures far exceed the
approximate 100 C/EBPd target genes previously identiﬁed through
ChIPechip assays in a previous study [8] and demonstrates the
sensitivity of our combined ChIP-SEQ and cDNA microarray
approach. Taken together our data demonstrates that C/EBPb and
C/EBPd isoforms interact promiscuously with the mouse genome
through direct interaction multiple C/EBP-binding sites. Moreover,
the fact that C/EBPd speciﬁcally interacts with over 1000 genes,
independently of C/EBPb, suggests that C/EBPd may play a unique
and speciﬁc role in the control of cell behaviour through the inde-
pendent regulation of multiple gene regulatory networks.
3.3. Identiﬁcation of genes whose expression is speciﬁcally
regulated by C/EBPd
Results this far indicate that there are many regulatory C/EBPd
binding sitesdistributed throughout themousegenome.Accordingly,
the identities of genes that contain C/EBPd binding sites are diverse
and don’t immediately describe shared functions (Supplementary
Data Set 1). The same can be said for C/EBPb-interacting genes(Supplementary Data Set 1). Therefore, in order to further delineate
the function of C/EBPd in MEFs we carried out CLUSTER analysis [18]
on the F/R-induced gene expression changes that were identiﬁed by
both cDNAmicroarray and SEQ analysis (Supplementary Data Set 2).
CLUSTERs were generated for gene expression changes associated
with C/EBPb (Fig. 3), C/EBPd (Fig. 4) and shared (C/EBPb plus C/EBPd;
Fig. 5) ChIP-SEQ and therefore represent genes that are potentially
cis-regulated by C/EBPs b and/or d. From these results in can be seen
that F/R stimulation effects the induction or suppression of a large
number of genes, where the direction of change is similar between
MEF WT and MEF / cells (Figs. 3e5). This indicates that although
C/EBPs b and/or d physically interact with these genes, they do not
appear tobe required for transcriptional regulationbyF/R. Incontrast,
CLUSTER analysis did reveal a number of gene groups (the enlarged
portions of Figs. 3e5) that share a common expression patterns
characterised by a directional change in gene expression relative to
MEFWT cells, in one or both of MEF C/EBPb / and/or MEF C/EBPd
/ cells, indicating a dependency on C/EBPb and/or C/EBPd for the
expression change. However, examining the majority of gene iden-
tities from C/EBPd-dependent CLUSTERs, it is not immediately clear
J. Wiejak et al. / Biomaterials 34 (2013) 1967e19791978which genesmight bedirectly responsible for the effects of C/EBPd on
cell adhesion, migration and spreading that we observed on planar
and nanometric growth surfaces (Fig. 1). We did note, however, that
the RHO guanine nucleotide exchange factor 33 (ARHGEF33)
appeared to be up-regulated in F/R-stimulated C/EBPd / cells
(Fig. 4), indicating a possible link between C/EBPd and the regulation
of the tubulin cytoskeleton.
Surprisingly we could not ﬁnd any other C/EBPd-regulated,
cytoskeleton linked gene identity in either of the C/EBPb or d ChIP-
SEQ lists, apart from RHO-family GTPase 3 (RND3), which was
associated with C/EBPb ChIP, and hence is likely to be trans-, rather
than cis-, activated byC/EBPd. Consistentwith a trans-activation role
for C/EBPd, we did ﬁnd a number of genes encoding cytoskeleton
components in Fig. 6 (tubulin b2 (TUBB2), Keratin 16 (KRT16) and
Keratin 20 (KRT20)), which details a CLUSTER of gene expression
changes that do not match with ChIP-SEQ and therefore represent
genes that are possibly trans-regulated by C/EBPs b and/or d. Trans-
regulation by C/EBPd could occur through either the induction of
expressionof additional, “tertiary”, transcription factor(s) or through
the activation of autocrine/paracrine signalling mechanisms. Inter-
estingly, in this respect, F/R treatment was found to up-regulate the
expression of the gene encoding the autocrine/paracrine cytokine
interleukin 6 (IL6), which is a C/EBPd-interacting gene whose
expression was further enhanced in MEF C/EBPd / cells (Fig. 4).
We conﬁrmed this observation by RT-PCR analysis of IL6 mRNA
levels in C/EBPWTandC/EBP/ cells (Fig. 7b) and contrasted these
effects with the expression levels of the transcription factor nuclear
receptor (NR) 4a3 and the signal transduction intermediate, insulin
receptor substrate (IRS) 1, whose mRNA levels were either induced
or repressed, respectively, following F/R treatment, but were unaf-
fected by knockout of the C/EBPd gene (Fig. 7b). Moreover, RT-PCR
analysis conﬁrmed that the genes encoding TUBB2, RND3, KRT16
and KRT20 were also induced by F/R treatment, consistent with
a potential intermediary role for IL6, however only Krt20 was the
only cytoskeletal component to be further induced following C/EBPd
deletion, whereas TUBB2 and KRT16 expression was suppressed
(Fig. 7a). Basal levels of RND3 levels were enhanced in MEF C/EBP
/ cells, whereas actin levels were unchanged, demonstrating that
C/EBPd is a general repressor of RND3 gene activity (Fig. 7a).
Together these results demonstrate that C/EBPd plays a central
role in the regulated expression of cytoskeleton components
(TUBB2, KRT16 and KRT20) and cytoskeleton regulators (ARHGEF33
and RND3) in MEFs. Since no direct interaction was detected
between C/EBPd and the genes encoding these cytoskeletal
components, it is likely that an intermediary, trans-activating
element, such as C/EBPd-regulated IL-6 (Fig. 7b), may be required
for their regulation. These observationsmaygo someway to explain
the requirement for C/EBPd for proper adhesion and spreading on
planar and nanometric growth surfaces described in Fig. 1.
3.4. The role of SOCS3 in spreading and contact guidance on
nanometric grooves
Another potential target for IL6-mediated, C/EBPd-dependent
trans-activation is the suppressor of cytokine signalling 3 (SOCS3)
gene. SOCS3 is known to be a direct target of IL6-receptor activa-
tion, mediated by tyrosine phosphorylated STAT3 transcription
factors [23]. Moreover, we have shown that SOCS3 gene induction
is absolutely required for efﬁcient SOCS3 induction by F/R in
vascular endothelial cells [17]. In the present study, we identiﬁed
SOCS3 as being induced by C/EBPd-dependent F/R treatment of
MEFs in microarray experiments (Fig. 6), Western blotting (Fig. 8a)
and RT-PCR (Fig. 8b), but not in ChIP-SEQ analysis. The SOCS3 gene
encodes an E3 ubiquitin ligase which targets focal adhesion-
associated FAK tyrosine kinase for proteolytic degradation [24,25]compared the abilities of MEF WT and MEF SOCS3 / cell to
attach and contact align to ﬂat, 240 nm and 540 nm grooved
growth surfaces (Fig. 9). We found that, as with previous experi-
ments, MEF WT cells attached and aligned to nanometric grooves
effectively (Fig. 9a). In contrast, MEF SOCS3 cells had an altered
morphology, characterised by enhanced vinculin expression, and
failed to contact align to either 240 nm or 540 nm grooves (Fig. 9a
and b). Consistent with a role for SOCS3 in controlling contact
guidance, SOCS3 protein levels were found to be signiﬁcantly
reduced in MEF WT cells (Fig. 9c). In contrast to MEF SOCS3 /
cells, MEF FAK / cells did not show any appreciable difference in
their ability to adhere and contact align to nanometric grooves
(Supplementary Fig. 3a and b). This indicates that the requirement
of SOCS3 for efﬁcient alignment to nanometric grooves is inde-
pendent of it ability to regulate FAK protein levels in cells.
4. Conclusions
In summary, we have used genomic analysis to demonstrate
that C/EBPd is a transcription factor that is required for efﬁcient
attachment, spreading and alignment to nanometric grooves. This
appears to occur through the trans-activation of genes encoding
inducible cell signalling elements, such as SOCS3, cytoskeletal
components, such as TUBB2, KRT16 and KRT20, and cytoskeletal
regulators, such as ARHGEF33 and RND3. A possible mechanism for
this trans-activation is through the cis-regulated induction of
autocrine/paracrine mediators, such as IL6. Of these newly identi-
ﬁed, C/EBPd-regulated genes, SOCS3 was found to be absolutely
required for cells to be able to attach, align and spread on nano-
metric grooves. The fact that the effects of C/EBPd knockout on the
interaction with nanometric grooves are much more subtle than
those observed with SOCS3 knockout, suggests that the effects
brought about by the loss of cellular C/EBPd can, to some extent, be
compensated for by cellular C/EBPb, which we ﬁnd to interact and
regulate many of the same genes as C/EBPd (Fig. 2b). Overall this
study demonstrates the complexity of C/EBPd-controlled gene
regulation and its importance for determining the nature of cell
interactions with extracellular, nanometric cues.
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